Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Veracyte, Inc. - Common Stock
(NQ:
VCYT
)
43.16
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Veracyte, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
September 28, 2025
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025
September 24, 2025
From
Veracyte, Inc.
Via
Business Wire
Earnings Scheduled For August 6, 2025
↗
August 06, 2025
Via
Benzinga
Earnings Scheduled For May 7, 2025
↗
May 07, 2025
Via
Benzinga
Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting
September 09, 2025
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
August 29, 2025
From
Veracyte, Inc.
Via
Business Wire
Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test
August 26, 2025
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
August 27, 2025
From
Veracyte, Inc.
Via
Business Wire
Veracyte Inc (NASDAQ:VCYT) Emerges as a Strong Value Pick with Solid Fundamentals and Growth Potential
↗
August 13, 2025
Veracyte (VCYT) emerges as a potential value stock with strong valuation, profitability, and growth metrics in the biotech sector, backed by solid financial health and cash flow potential.
Via
Chartmill
Veracyte (VCYT) Q2 Revenue Jumps 14%
↗
August 07, 2025
Via
The Motley Fool
Veracyte Announces Second Quarter 2025 Financial Results
August 06, 2025
From
Veracyte, Inc.
Via
Business Wire
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics
↗
July 26, 2025
Ark Invest traded in VCYT, IRDM, CRSP, KTOS, ABSI, VEEV, ADPT, and GH. Mainly focused on healthcare innovation.
Via
Benzinga
VERACYTE INC (NASDAQ:VCYT) – An Undervalued Stock with Strong Fundamentals
↗
July 21, 2025
VERACYTE INC (NASDAQ:VCYT) is an undervalued biotech stock with strong financial health, solid profitability, and impressive growth prospects, making it a candidate for value investors.
Via
Chartmill
Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025
July 17, 2025
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025
July 08, 2025
From
Veracyte, Inc.
Via
Business Wire
Cathie Wood's Ark Invest Adds Airbnb, AMD, Shopify To Portfolio, Slashes Stake In Circle Internet
↗
June 21, 2025
Via
Benzinga
Cathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D Systems
↗
June 07, 2025
Ark Invest made notable trades on Friday, including purchasing shares of Veracyte Inc. and selling shares of 3D Systems Corp.
Via
Benzinga
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research
May 28, 2025
From
Veracyte, Inc.
Via
Business Wire
VERACYTE INC (NASDAQ:VCYT) – A Promising Affordable Growth Stock in Biotechnology
↗
May 28, 2025
VERACYTE INC (NASDAQ:VCYT) is a biotechnology stock with strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth...
Via
Chartmill
Veracyte to Participate in Upcoming Investor Conferences
May 20, 2025
From
Veracyte, Inc.
Via
Business Wire
Breaking Down Veracyte: 7 Analysts Share Their Views
↗
May 08, 2025
Via
Benzinga
Veracyte Announces First Quarter 2025 Financial Results
May 07, 2025
From
Veracyte, Inc.
Via
Business Wire
Veracyte Inc (NASDAQ:VCYT) – An Affordable Growth Stock to Watch
↗
May 02, 2025
Veracyte Inc (NASDAQ:VCYT) – An Affordable Growth Stock to Watch
Via
Chartmill
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms
↗
April 26, 2025
ARK Invest made significant trades in NTLA, META, VCYT, SYM, BIDU, and PATH. These moves come amidst changes in stock prices. Read more for full details.
Via
Benzinga
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
April 25, 2025
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting
April 22, 2025
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release
April 21, 2025
From
Veracyte, Inc.
Via
Business Wire
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
↗
April 17, 2025
A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.
Via
Investor's Business Daily
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025
April 16, 2025
From
Veracyte, Inc.
Via
Business Wire
Despite its growth, VERACYTE INC (NASDAQ:VCYT) remains within the realm of affordability.
↗
April 12, 2025
Discover VERACYTE INC, an undervalued growth gem. NASDAQ:VCYT is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing...
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
